GlaxoSmithKline expects to record a legal charge of 1.57 billion pounds ($2.4 billion) for the second quarter after settling the substantial majority of claims relating to its diabetes pill Avandia.

The British-based drugmaker said on Thursday the charge would cover not only settlements for Avandia but also other long-standing legal cases, including an investigation into its former factory at Cidra in Puerto Rico and anti-trust litigation over antidepressant Paxil.

The after-tax cost of the legal charge will be 1.35 billion pounds.

Glaxo did not specify the amount it was setting aside to settle liability claims over Avandia, which U.S. health advisers recommended on Wednesday should be allowed to stay on the market but with additional warnings over heart risks.

But Glaxo said the agreement in principle over Cidra was for a total of 500 million pounds.

(Reporting by Ben Hirschler; Editing by Dan Lalor)

($1 = 0.6580 pound)

Puerto rico Glaxosmithkline